



# IMPROVING OUTCOMES IN FEE FOR SERVICE MEDICARE

MAY 12, 2003 THIRD NATIONAL DISEASE MANAGEMENT SUMMIT

David Kreiss, Esq.

Special Assistant, Office of the Administrator Centers for Medicare & Medicaid Services



# Improving Outcomes in FFS Medicare

# Where we are today:


35,000,000 beneficiaries

• \$200,000,000,000 + annually

 No system of producing and rewarding performance improvement on a large scale



#### Complexity of Managing Chronic Diseases





#### **DHHS Initiatives in FFS Medicare**

- Public Reporting on Performance
  - Nursing Homes
  - □ Home Health
  - Hospitals
- Hospital Quality Incentives Demonstration
- Physician Group Practice Quality Bonus
- Disease Management Initiatives
  - □ Congressionally-mandated (BIPA)
  - Capitated
  - □ Population-Based



# Advantages of Population-Based Contracting

Sets measurable goals for target populations

Ties payment to performance

Scalable, replicable, adaptable



# Potential vehicle for driving improvement in population health

Cost-effectively

Rapidly

- Addressing IOM priority areas
- Reducing health disparities



# **Key Features**

- Offers <u>guidance in self-care</u> to targeted beneficiaries
- Offers <u>clinical information support</u> to their healthcare providers



# **High Priority**


 Programs designed to help participants manage all their co-morbidities

 Beginning with at-risk populations, e.g., beneficiaries who have congestive heart failure (CHF) or diabetes among their diagnoses



#### Targeting Beneficiaries at Risk





Source: Medicare Current Beneficiary Survey Cost and Use Files




#### Why CHF as a trigger condition?


- Available guidelines (e.g., monitor fluid build-up)
- Good tools available to influence beneficiary behavior
- Intuitive value of support services to beneficiaries
- Evidence of significant clinical and financial gains (e.g., reduce re-admissions, ER visits, total claims costs)
- No major physician behavior changes required
- Can identify beneficiaries from available data
- Potential contractors with expertise
- Fits Medicare payment system well to produce savings



#### CHF Prevalence in FFS Medicare, 2001

Estimated Prevalence of CHF, All non-HMO Medicare, 2001









# Why diabetes as a trigger condition?

Prevalence of diagnosed diabetes, all ages, by state and year





# Diabetes Highest among Minorities





Source: Centers for Disease Control and Prevention - Age-Specific Prevalence of Diagnosed Diabetes, by Race/Ethnicity and Sex, United States, 1999



#### Diabetes Prevalence FFS Medicare, 2001

Estimated Prevalence of Diabetes, All non-HMO Medicare, 2001







# **Improving Outcomes in FFS Medicare**

State	> 500,000 Medicare Beneficiaries	> 17% Diabetes or > 12% CHF in Medicare	> 16% Minorities in Medicare	Low Avg. Quality Rank	> 20% Pop. Rural
Alabama	√	√	√	√ (42)	<b>V</b>
Florida	V	√	√	√ (41)	
Georgia	V	√	$\sqrt{}$	√ (47)	$\sqrt{}$
Illinois	V	√	$\sqrt{}$	√ (46)	
Louisiana	V		$\sqrt{}$	√ (51)	$\sqrt{}$
New Jersey	$\sqrt{}$		√	√ (43)	
South Carolina	V	√	$\sqrt{}$	√ (32)	$\sqrt{}$
Texas	$\sqrt{}$		$\checkmark$	√ (49)	
Indiana	V	√	*	√ (27)	√
Michigan	√	√	*	√ (26)	√
Pennsylvania	√	√	*	√ (31)	√

<sup>\*</sup> Applies to Metropolitan Statistical Area, not entire state



# **Potential Partners**

Insurers

HMOs

DMOs

Provider systems

Consortia



#### **Contractor Selection Considerations**

- Track record
- Information and communications systems
- Staff expertise clinical, analytic
- Integrated guidelines
- Scalable operations
- Solvency
- Bid



#### Financial Model

- Per member per month payment for DM services
- Performance guarantees (fees at risk)
  - Operational measures
  - □ Adherence to guidelines (including co-morbidities)
  - □ Annual savings (all claims for target population)
- Compare experimental and control groups



# **Targeted PDM Outcomes**

#### **Example**

 For beneficiaries with a CHF admission within the preceding 12 months, reduce re-admissions by 20% and Medicare annual claims costs by 5% compared to control groups